Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

Bruno Francois, Simon Lambden, Sebastien Gibot, Marc Derive, Aurelie Olivier, Valerie Cuvier, Stephan Witte, Jean-Marie Grouin, Jean Jacques Garaud, Margarita Salcedo-Magguilli, Mitchell Levy, Pierre-François Laterre, Bruno Francois, Simon Lambden, Sebastien Gibot, Marc Derive, Aurelie Olivier, Valerie Cuvier, Stephan Witte, Jean-Marie Grouin, Jean Jacques Garaud, Margarita Salcedo-Magguilli, Mitchell Levy, Pierre-François Laterre

Abstract

Introduction: Septic shock is the subgroup of patients with sepsis, which presents as vasopressor dependence, an elevated blood lactate concentration and is associated with a mortality of at least 30%. Expression of the triggering receptor expressed on myeloid cells 1 (TREM-1) pathway, measured using a serum biomarker of pathway activation (soluble TREM-1, sTREM-1) has been associated with outcome in septic shock. Preclinical and early phase patient data suggest that therapeutic modulation of this pathway may improve survival.

Methods and analysis: Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock is a phase IIb randomised controlled trial that will take place in up to 50 centres in seven countries and recruit 450 patients with septic shock to receive either placebo or one of two doses of nangibotide, a novel regulator of the TREM-1 pathway. The primary outcome will be the impact of nangibotide therapy on the change in Sequential Organ Failure Assessment score from a baseline determined before initiation of study drug therapy. This will be assessed first in the patients with an elevated sTREM-1 level and then in the study population as a whole. In addition to safety, secondary outcomes of the study will include efficacy of nangibotide in relation to sTREM-1 levels in terms of organ function, mortality and long-term morbidity. This study will also facilitate the development of a novel platform for the measurement of sTREM-1 at the point of care.

Ethics and dissemination: The study has been approved by the responsible ethics committees/institutional review boards in all study countries: Belgium: Universitair Ziekenhuis Antwerpen, France: CPP Ile de France II, Denmark: Region Hovedstaden, Spain: ethics committee from Valld'Hebron Hospital, Barcelona, Finland: Tukija, Ireland: St. James' Hospital (SJH) / Tallaght University Hospital (TUH) Joint Research Ethics Committee, USA: Lifespan, Providence TRIAL REGISTRATION NUMBERS: EudraCT Number: 2018-004827-36 and NCT04055909.

Keywords: adult intensive & critical care; clinical trials; infectious diseases.

Conflict of interest statement

Competing interests: The authors have the following interests: SL, MS-M, JJG, SW and VC are employees of Inotrem SA. BF is the principal investigator of the trial and is a member of the steering committee.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow chart. CCC, Central Co-ordinating centre; EoS, end of study; Fu, follow-up; LD, loading dose or matching placebo.

References

    1. Singer M, Deutschman CS, Seymour CW, et al. . The third International consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801–10. 10.1001/jama.2016.0287
    1. Shankar-Hari M, Phillips GS, Levy ML, et al. . Developing a new definition and assessing new clinical criteria for septic shock: for the third International consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:775–87. 10.1001/jama.2016.0289
    1. Lone NI, Walsh TS. Impact of intensive care unit organ failures on mortality during the five years after a critical illness. Am J Respir Crit Care Med 2012;186:640–7. 10.1164/rccm.201201-0059OC
    1. Lone NI, Gillies MA, Haddow C, et al. . Five-Year mortality and hospital costs associated with surviving intensive care. Am J Respir Crit Care Med 2016;194:198–208. 10.1164/rccm.201511-2234OC
    1. Chang HJ, Lynm C, Glass RM. JAMA patient page. sepsis. JAMA 2010;304:1856. 10.1001/jama.304.16.1856
    1. Iwashyna TJ, Ely EW, Smith DM, et al. . Long-Term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010;304:1787–94. 10.1001/jama.2010.1553
    1. Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Intensive Care Med 2018;44:925–8. 10.1007/s00134-018-5085-0
    1. Opal SM, Dellinger RP, Vincent JL. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med 2014. (published Online First: 2014/04/11).
    1. Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011;306:2614–5. 10.1001/jama.2011.1853
    1. Lambden S, Summers C. Bridging the translational gap: the challenges of novel drug development in critical care. In: Vincent J-L, ed. Annual update in intensive care and emergency medicine 2017. Cham: Springer International Publishing, 2017: 375–88.
    1. Cohen J, Vincent J-L, Adhikari NKJ, et al. . Sepsis: a roadmap for future research. Lancet Infect Dis 2015;15:581–614. 10.1016/S1473-3099(15)70112-X
    1. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164:4991–5. 10.4049/jimmunol.164.10.4991
    1. Bouchon A, Facchetti F, Weigand MA, et al. . Trem-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410:1103–7. 10.1038/35074114
    1. Derive M, Massin F, Gibot S. Triggering receptor expressed on myeloid cells -1 as a new therapeutic target during inflammatory diseases. Self Nonself 2010;1:225–30. 10.4161/self.1.3.12891
    1. Washington AV, Schubert RL, Quigley L, et al. . A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets. Blood 2004;104:1042–7. 10.1182/blood-2004-01-0315
    1. Xiao W, Mindrinos MN, Seok J, et al. . A genomic storm in critically injured humans. J Exp Med 2011;208:2581–90. 10.1084/jem.20111354
    1. Brenner T, Uhle F, Fleming T, et al. . Soluble TREM-1 as a diagnostic and prognostic biomarker in patients with septic shock: an observational clinical study. Biomarkers 2017;22:63–9. 10.1080/1354750X.2016.1204005
    1. Washington AV, Gibot S, Acevedo I, et al. . TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest 2009;119:1489–501. 10.1172/JCI36175
    1. Derive M, Bouazza Y, Sennoun N, et al. . Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. J Immunol 2012;188:5585–92. 10.4049/jimmunol.1102674
    1. Lemarié J, Boufenzer A, Popovic B, et al. . Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Failure 2015;2:90–9. 10.1002/ehf2.12029
    1. Derive M, Boufenzer A, Bouazza Y, et al. . Effects of a TREM-Like transcript 1–Derived peptide during hypodynamic septic shock in pigs. Shock 2013;39:176–82. 10.1097/SHK.0b013e31827bcdfb
    1. François BWX, Ferrer R, Mira JP. Sepsis 2018. Intensive Care Medicine Experimental 2018;6:1–33.
    1. François B, Wittebole X, Ferrer R, et al. . Nangibotide in patients with septic shock: a phase 2A randomized controlled clinical trial. Intensive Care Med 2020;46:1425–37. 10.1007/s00134-020-06109-z
    1. Knaus WA, Draper EA, Wagner DP, et al. . APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.
    1. Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol 2020;16:20–31. 10.1038/s41581-019-0199-3
    1. European Medicines Agency . CPMP/EWP/4713/2003. guideline on clinical investigation of medicinal products for the treatment of sepsis. Domenico Scarlattilaan, 61083 HS Amsterdam, The Netherlands: European Medicines Agency, 2006.
    1. de Grooth H-J, Geenen IL, Girbes AR, et al. . SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care 2017;21:38. 10.1186/s13054-017-1609-1
    1. Lambden S, Laterre PF, Levy MM, et al. . The SOFA score—development, utility and challenges of accurate assessment in clinical trials. Crit Care 2019;23:374. 10.1186/s13054-019-2663-7
    1. Seymour CW, Kennedy JN, Wang S, et al. . Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019;321:2003. 10.1001/jama.2019.5791
    1. Davenport EE, Burnham KL, Radhakrishnan J, et al. . Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016;4:259–71. 10.1016/S2213-2600(16)00046-1

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi